GSK plc (GLAXF)
OTCMKTS · Delayed Price · Currency is USD
18.76
-0.18 (-0.95%)
Jul 29, 2025, 3:21 PM EDT
GSK plc Revenue
GSK plc had revenue of 7.99B GBP in the quarter ending June 30, 2025, with 1.29% growth. This brings the company's revenue in the last twelve months to 31.63B, up 0.59% year-over-year. In the year 2024, GSK plc had annual revenue of 31.38B with 3.46% growth.
Revenue (ttm)
31.63B GBP
Revenue Growth
+0.59%
P/S Ratio
1.81
Revenue / Employee
460.90K GBP
Employees
68,629
Market Cap
78.44B USD
Revenue Chart
* This company reports financials in GBP.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 31.38B | 1.05B | 3.46% |
Dec 31, 2023 | 30.33B | 1.00B | 3.42% |
Dec 31, 2022 | 29.32B | 4.63B | 18.74% |
Dec 31, 2021 | 24.70B | 342.00M | 1.40% |
Dec 31, 2020 | 24.35B | -9.40B | -27.85% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo, Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 84.04M |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.70M |
GSK plc News
- 9 hours ago - GSK Lifts Outlook as Specialty Medicines Drive Profit Beat Amid Tariff Uncertainty - Investomania
- 11 hours ago - GSK expects annual sales and profit at top end of forecast range - Reuters
- 1 day ago - GSK Q2 2025 Earnings Preview - Seeking Alpha
- 2 days ago - GSK: I Foresee Only Very Modest Upside Here Even If Blenrep Gets FDA Approval - Seeking Alpha
- 2 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK - GlobeNewsWire
- 2 days ago - After Merck, Chinese Biotech Hengrui Pharma Collaborates With GSK In Worth $12 Billion Pact - Benzinga
- 2 days ago - FTSE Rises as US-EU Trade Deal Lifts Mood - Investomania
- 2 days ago - GSK Enters $12 Billion Collaboration with Hengrui Pharma - GuruFocus